The Long Investor notes Hims & Hers stock squeezed between a breakout level and its 200-day average, with earnings due November 9 or possible peptide news as a trigger.
Recap by typeshit. Post by The Long Investor on X.
At the SIO congress in Palermo, specialists flagged short real-world adherence and no national reimbursement in Italy. Oral semaglutide and orforglipron are expected there in 2027.
A short clip from Dr. Reese pushing back on the rush toward peptides as an easy shortcut, with little detail beyond that.
11:54
Ryan Sims of Optimal Health Project gives a follow-up on how things have gone in the months since his 35-pound loss on the experimental drug.
The Tico Times reports Costa Rica's public system is considering offering GLP-1 weight loss drugs to patients. Tap through for where the discussion stands.
A fresh warning points to more people ending up in hospital after taking peptides that aren't approved. Tap through for who issued it.
A short personal check-in from a creator who tags her post with tirzepatide. No numbers or details beyond the update itself.
Loading…